| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
Departments of 1 Hematopathology, 2 Molecular Pathology, and 3 Molecular Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Requests for reprints: George Z. Rassidakis, Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Unit 54, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-745-2535; Fax: 713-792-7273; E-mail: gzrassidakis{at}mdanderson.org.
Anaplastic lymphoma kinase (ALK)–positive anaplastic large cell lymphoma (ALCL) frequently carries the t(2;5)(p23;q35) resulting in aberrant expression of chimeric nucleophosmin-ALK. Previously, nucleophosmin-ALK has been shown to activate phosphatidylinositol 3-kinase (PI3K) and its downstream effector, the serine/threonine kinase AKT. In this study, we hypothesized that the mammalian target of rapamycin (mTOR) pathway, which functions downstream of AKT, mediates the oncogenic effects of activated PI3K/AKT in ALK+ ALCL. Here, we provide evidence that mTOR signaling phosphoproteins, including mTOR, eukaryotic initiation factor 4E–binding protein-1, p70S6K, and ribosomal protein S6, are highly phosphorylated in ALK+ ALCL cell lines and tumors. We also show that AKT activation contributes to mTOR phosphorylation, at least in part, as forced expression of constitutively active AKT by myristoylated AKT adenovirus results in increased phosphorylation of mTOR and its downstream effectors. Conversely, inhibition of AKT expression or activity results in decreased mTOR phosphorylation. In addition, pharmacologic inhibition of PI3K/AKT down-regulates the activation of the mTOR signaling pathway. We also show that inhibition of mTOR with rapamycin, as well as silencing mTOR gene product expression using mTOR-specific small interfering RNA, decreased phosphorylation of mTOR signaling proteins and induced cell cycle arrest and apoptosis in ALK+ ALCL cells. Cell cycle arrest was associated with modulation of G1-S-phase regulators, including the cyclin-dependent kinase inhibitors p21waf1 and p27kip1. Apoptosis following inhibition of mTOR expression or function was associated with down-regulation of antiapoptotic proteins, including c-FLIP, MCL-1, and BCL-2. These findings suggest that the mTOR pathway contributes to nucleophosmin-ALK/PI3K/AKT-mediated tumorigenesis and that inhibition of mTOR represents a potential therapeutic strategy in ALK+ ALCL. (Cancer Res 2006; 66(13): 6589-97)
This article has been cited by other articles:
|
|
 |
|
  A. C. Faber, D. Li, Y. Song, M.-C. Liang, B. Y. Yeap, R. T. Bronson, E. Lifshits, Z. Chen, S.-M. Maira, C. Garcia-Echeverria, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition PNAS, November 17, 2009; 106(46): 19503 - 19508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lim, M. L. Carlson, D. K. Crockett, G. C. Fillmore, D. R. Abbott, O. F. Elenitoba-Johnson, S. R. Tripp, G. Z. Rassidakis, L. J. Medeiros, P. Szankasi, et al. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways Blood, August 20, 2009; 114(8): 1585 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bonvini, E. Zorzi, L. Mussolin, G. Monaco, M. Pigazzi, G. Basso, and A. Rosolen The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity Haematologica, July 1, 2009; 94(7): 944 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Singh, J. H. Cho-Vega, Y. Davuluri, S. Ma, F. Kasbidi, C. Milito, P. A. Lennon, E. Drakos, L. J. Medeiros, R. Luthra, et al. Sonic Hedgehog Signaling Pathway Is Activated in ALK-Positive Anaplastic Large Cell Lymphoma Cancer Res., March 15, 2009; 69(6): 2550 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ackler, Y. Xiao, M. J. Mitten, K. Foster, A. Oleksijew, M. Refici, S. Schlessinger, B. Wang, S. R. Chemburkar, J. Bauch, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo Mol. Cancer Ther., October 1, 2008; 7(10): 3265 - 3274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Kuo, P.-Y. Yeh, L.-T. Chen, M.-S. Wu, C.-W. Lin, K.-H. Yeh, Y.-S. Tzeng, J.-Y. Chen, P.-N. Hsu, J.-T. Lin, et al. Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma Blood, October 1, 2008; 112(7): 2927 - 2934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Nakamura, E. Garcia, and R. O. Pieper S6K1 Plays a Key Role in Glial Transformation Cancer Res., August 15, 2008; 68(16): 6516 - 6523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Mills, Y. Hippo, F. Robert, S. M. H. Chen, A. Malina, C.-J. Lin, U. Trojahn, H.-G. Wendel, A. Charest, R. T. Bronson, et al. mTORC1 promotes survival through translational control of Mcl-1 PNAS, August 5, 2008; 105(31): 10853 - 10858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Sanders, A. Lakhani, C. Phornphutkul, K.-Y. Wu, and P. A. Gruppuso The effect of rapamycin on DNA synthesis in multiple tissues from late gestation fetal and postnatal rats Am J Physiol Cell Physiol, August 1, 2008; 295(2): C406 - C413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Rizzieri, E. Feldman, J. F. DiPersio, N. Gabrail, W. Stock, R. Strair, V. M. Rivera, M. Albitar, C. L. Bedrosian, and F. J. Giles A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies Clin. Cancer Res., May 1, 2008; 14(9): 2756 - 2762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Qian, H. Du, B. F. King, S. Kumar, P. G. Dean, F. G. Cosio, and V. E. Torres Sirolimus Reduces Polycystic Liver Volume in ADPKD Patients J. Am. Soc. Nephrol., March 1, 2008; 19(3): 631 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Tartari, R. H. Gunby, A. M. L. Coluccia, R. Sottocornola, B. Cimbro, L. Scapozza, A. Donella-Deana, L. A. Pinna, and C. Gambacorti-Passerini Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase J. Biol. Chem., February 15, 2008; 283(7): 3743 - 3750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Feng, R. E. Brown, C. D. Trung, W. Li, L. Wang, T. Khoury, S. Alrawi, J. Yao, K. Xia, and D. Tan Morphoproteomic Profile of mTOR, Ras/Raf Kinase/ERK, and NF-{kappa}B Pathways in Human Gastric Adenocarcinoma Ann. Clin. Lab. Sci., January 1, 2008; 38(3): 195 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Staber, P. Vesely, N. Haq, R. G. Ott, K. Funato, I. Bambach, C. Fuchs, S. Schauer, W. Linkesch, A. Hrzenjak, et al. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling Blood, November 1, 2007; 110(9): 3374 - 3383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Amin and R. Lai Pathobiology of ALK+ anaplastic large-cell lymphoma Blood, October 1, 2007; 110(7): 2259 - 2267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Leventaki, E. Drakos, L. J. Medeiros, M. S. Lim, K. S. Elenitoba-Johnson, F. X. Claret, and G. Z. Rassidakis NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma Blood, September 1, 2007; 110(5): 1621 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Y. Follo, S. Mongiorgi, C. Bosi, A. Cappellini, C. Finelli, F. Chiarini, V. Papa, M. Libra, G. Martinelli, L. Cocco, et al. The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation Cancer Res., May 1, 2007; 67(9): 4287 - 4294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Peponi, E. Drakos, G. Reyes, V. Leventaki, G. Z. Rassidakis, and L. J. Medeiros Activation of Mammalian Target of Rapamycin Signaling Promotes Cell Cycle Progression and Protects Cells from Apoptosis in Mantle Cell Lymphoma Am. J. Pathol., December 1, 2006; 169(6): 2171 - 2180. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
